Home Cart Sign in  
Chemical Structure| 133040-01-4 Chemical Structure| 133040-01-4

Structure of Eprosartan
CAS No.: 133040-01-4

Chemical Structure| 133040-01-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure.

Synonyms: SKF-108566J free base

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Eprosartan

CAS No. :133040-01-4
Formula : C23H24N2O4S
M.W : 424.51
SMILES Code : O=C(O)C1=CC=C(CN2C(/C=C(C(O)=O)\CC3=CC=CS3)=CN=C2CCCC)C=C1
Synonyms :
SKF-108566J free base
MDL No. :MFCD00897872

Safety of Eprosartan

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319
Precautionary Statements:P305+P351+P338

Related Pathways of Eprosartan

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01715584 Hypertension Phase 4 Recruiting December 31, 2019 Canada, Ontario ... More >> London Health Sciences Centre - Victoria Campus Recruiting London, Ontario, Canada, N6A 5W9 Contact: Craig J Railton, MD, PhD    519 685 8500 ext 58525    Craig.Railton@lhsc.on.ca    Principal Investigator: Craig J Railton, MD, PhD          Sub-Investigator: Jonathan Fairbairn, BSc          Sub-Investigator: George Nicoloau, MD          Sub-Investigator: Robert Gros, PhD          Sub-Investigator: Jason Franklin, MD          Sub-Investigator: John Yoo, MD          Sub-Investigator: Kevin Fung, MD          Sub-Investigator: Anthony Nichols, MD          Sub-Investigator: Danielle McNeil, MD Less <<
NCT02817360 Heart Diseases ... More >> Diabetes Mellitus, Type 2 Less << Phase 4 Recruiting February 2021 Austria ... More >> Internistische Ordination Recruiting Mödling, Niederösterreich, Austria, 2340 Contact: Christian Feinböck, MD    +43 2236 869 142    office@dr-feinboeck.at    Contact: Christiane Feinböck    +43 2236 869 142    office@dr-feinboeck.at    Sub-Investigator: Egbert Seyfried, MD          Principal Investigator: Christian Feinböck, MD          Klinischen Abteilung für Endokrinologie und Diabetologie MU Graz Recruiting Graz, Steiermark, Austria, 8036 Contact: Harald Sourij    +43-316-385-80363    ha.sourij@medunigraz.at    Contact: Michael Zink    +43-680-128-5120    m.zink@medunigraz.at    Sub-Investigator: Julia Mader, MD Prof          Sub-Investigator: Eva Novak, MD          Sub-Investigator: Caren Sourij, MD          Konventhospital der Barmherzigen Brüder Abteilung für Innere Medizin Recruiting Linz, Upper Austria, Austria, 4021 Contact: Martin Clodi, Prof.Dr.       martin.clodi@bblinz.at    Principal Investigator: Martin Clodi, Prof.Dr.          Sub-Investigator: Michael Resl, Dr.          Krankenanstalt Rudolfstiftung, 1. Medizinische Abteilung Recruiting Vienna, Austria, 1030 Contact: Bernhard Ludvik, Prof.Dr.    +43 1 711 65 ext 2107    bernhard.ludvik@wienkav.at    Principal Investigator: Bernhard Ludvik, Prof.Dr.          Sub-Investigator: Eva-Christina Krzizek, Dr.          Sub-Investigator: Johanna Brix, Dr.          Sub-Investigator: Astrid Feder, Dr.          Sub-Investigator: Florian Hoellerl, Dr.          Medical University of Vienna Univ.Clinic for Internal Medicine II Department of Cardiology Recruiting Vienna, Austria, 1090 Contact: Martin Huelsmann, Doz.Dr.    +43 1 40400 ext 46140    martin.huelsmann@meduniwien.ac.at    Principal Investigator: Martin Huelsmann, Doz.Dr.          Sub-Investigator: Raphael Wurm, Dr.          Univ. Klinik für Innere Medizin III Med. Uni Wien Recruiting Vienna, Austria, 1090 Contact: Anton Luger, Prof.Dr.    00 43 1 40400 ext 43100    anton.luger@meduniwien.ac.at    Principal Investigator: Anton Luger, Prof.Dr.          Sub-Investigator: Michael Krebs, Prof.Dr.          Universitätsklinik für Augenheilkunde und Optometrie Medizinische Universität Wien Recruiting Vienna, Austria, 1090 Contact: Sonja Prager, Dr.    +43 1 40400 ext 79470    sonja.prager@meduniwien.ac.at    Principal Investigator: Sonja Prager, Dr.          Sub-Investigator: Julia Hafner, Dr.          Diabetes & Stoffwechselambulanz Gesundheitszentrum Wien Süd Recruiting Vienna, Austria, 1100 Contact: Helmut Brath, OA Dr.    +43 1 60122 ext 4264    helmut.brath@wgkk.at    Principal Investigator: Helmut Brath, OA Dr.          3. Med. Abtlg., KH Hietzing mit Neurologischem Zentrum Rosenhügel Recruiting Vienna, Austria, 1130 Contact: Rudolf Prager, Prof.Dr.    +43 1 80110 ext 2351    rudolf.prager@wienkav.at    Principal Investigator: Rudolf Prager, Prof.Dr.          Sub-Investigator: Slobodan Peric, Dr.          Zentrum für Klinische Studien Recruiting Wien, Austria, 1060 Contact: Ursula Hanusch, MD    +43 1 266 21 91    dr.hanusch@dieinternistin.com    Contact: Michaela Mauritz    +43 1 266 21 91    office@dieinternistin.com    Sub-Investigator: Marita Spak, MD          Netherlands Maastricht University Medical Center; Dep. Cardiology Recruiting Maastricht, Netherlands, 6202 Contact: Hans-Peter Brunner-La Rocca, MD Prof    +31 43-3877097    hp.brunnerlarocca@mumc.nl    Contact: Mireille Spanjers    +31 43-3877099    m.spanjers@mumc.nl    Sub-Investigator: Nick Marks, MD          Sub-Investigator: Wouter Robaeys, MD          New Zealand Christchurch Heart Institute Recruiting Christchurch, New Zealand, 8140 Contact: Richard Troughton, MD Prof    +64 3 364 1063    Richard.Troughton@cdhb.health.nz    Contact: Lorraine Skelton    +64 3 364 1063    lorraine.skelton@cdhb@health.nz    Principal Investigator: Richard Troughton, MD Prof Less <<
NCT00684489 Hypertension Not Applicable Completed - -
NCT01753206 - Completed - Korea, Republic of ... More >> Seoul National University Bundang Hospital Seongnam-si, Bundang-gu, Korea, Republic of, 463-717 Less <<
NCT02024100 - Unknown December 2016 Korea, Republic of ... More >> Seoul National University Bundang Hospital Recruiting Seongnam-si, Bundang-gu, Korea, Republic of, 463-717 Contact: Chang Hwan Yoon, MD          Principal Investigator: Chang Hwan Yoon, MD Less <<
NCT01562613 - Completed - -
NCT01087749 Kidney Disease Phase 1 Completed - United States, California ... More >> Clinical Reserach Center, UCSF San Francisco,, California, United States, 94143 Less <<
NCT01562613 - Completed - -
NCT00160160 Hypertension ... More >>Type 2 Diabetes Less << Not Applicable Completed - -
NCT01631227 Essential Hypertension Phase 3 Completed - Germany ... More >> Site Reference ID/Investigator# 74062 Berlin, Germany, 12627 Site Reference ID/Investigator# 74066 Bochum, Germany, 44787 Site Reference ID/Investigator# 74065 Dresden, Germany, 01067 Site Reference ID/Investigator# 93513 Dresden, Germany, 01307 Site Reference ID/Investigator# 93495 Essen, Germany, 45355 Site Reference ID/Investigator# 93515 Frankfurt, Germany, 60594 Site Reference ID/Investigator# 74060 Frankfurt, Germany, 60596 Site Reference ID/Investigator# 74063 Goerlitz, Germany, 02826 Site Reference ID/Investigator# 93494 Hamburg, Germany, 22143 Site Reference ID/Investigator# 93493 Karlsruhe, Germany, 76199 Site Reference ID/Investigator# 74061 Leipzig, Germany, 04103 Site Reference ID/Investigator# 74064 Magdeburg, Germany, 39104 Site Reference ID/Investigator# 93514 Nuremberg, Germany, 90402 Russian Federation Site reference ID/Investigator # 82515 Barnaul, Russian Federation, 656055 Site reference ID/Investigator # 82520 Kazan, Russian Federation, 420012 Site reference ID/Investigator # 82493 Kemerovo, Russian Federation, 650002 Site reference ID/Investigator # 82516 Kemerovo, Russian Federation, 650055 Site refernce ID/Investigator # 82521 Krasnodar, Russian Federation, 350086 Site reference ID/Investigator # 82495 Novosibirsk, Russian Federation, 630008 Site reference ID/Investigator # 82494 Novosibirsk, Russian Federation, 630047 Site reference ID/Investigator # 82525 Novosibirsk, Russian Federation, 630068 Site reference ID/Investigator # 82522 St. Petersburg, Russian Federation, 192283 Site reference ID/Investigator # 82517 St. Petersburg, Russian Federation, 194044 Site reference ID/Investigator # 82524 St. Petersburg, Russian Federation, 197022 Site reference ID/Investiragor # 82523 St. Petersburg, Russian Federation, 197022 Site reference ID/Investigator # 82519 St. Petersburg, Russian Federation, 198205 Site reference ID/Investigator # 82518 St. Petersburg, Russian Federation, 198260 Site reference ID/Investigator # 82527 St. Petersburg, Russian Federation, 199106 United Kingdom Site Reference ID/Investigator# 74057 Birmingham, United Kingdom, B15 2SQ Site Reference ID/Investigator# 74059 Cardiff, United Kingdom, CF14 5GJ Site Reference ID/Investigator# 74056 Chorley, United Kingdom, PR7 7NA Site Reference ID/Investigator# 74054 Glasgow, United Kingdom, G20 0SP Site reference ID/Investigator # 95456 Glasgow, United Kingdom, G45 9AW Site Reference ID/Investigator# 74053 Liverpool, United Kingdom, L22 0LG Site reference ID/Investigator # 95457 London, United Kingdom, EC1M 6BQ Site Reference ID/Investigator# 74055 Manchester, United Kingdom, M16 6SX Site reference ID/Investigator # 95455 Northwood, United Kingdom, HA6 2RN Site Reference ID/Investigator# 74058 Reading, United Kingdom, RG2 0TG Less <<
NCT00438945 Essential Hypertension Phase 4 Completed - Denmark ... More >> Department of Medical Research, Holstebro Hospital Holstebro, Denmark, 7500 Less <<
NCT01631227 - Completed - -
NCT00409903 Healthy Phase 4 Completed - Denmark ... More >> Department of Medical Research, Holstebro Hospital Holstebro, Denmark, 7500 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.36mL

0.47mL

0.24mL

11.78mL

2.36mL

1.18mL

23.56mL

4.71mL

2.36mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories